Urine Specimen Validity Testing: What Contamination Can Change

By Okorie Okorocha, JD, MS, MS

A urine drug-test result can be affected by more than the drug itself. Dilution, substitution, contamination, storage conditions, and chemical adulteration can change the specimen or interfere with a screening method. A scientifically defensible review separates those possibilities from a claim about what a person intentionally did.

Screening and specimen validity answer different questions

A drug screen asks whether the test response reached a decision threshold for a drug class or analyte. Specimen-validity testing asks whether the urine has characteristics consistent with an acceptable human urine specimen and whether particular forms of alteration may be present.

The two questions should not be collapsed. A negative drug screen does not establish that a specimen was valid. An unusual pH, creatinine, specific gravity, or oxidant result does not by itself prove a particular method of alteration or a person’s intent.

Dilution, substitution, and adulteration are not synonyms

Dilution generally refers to a specimen with reduced concentration, which may arise from fluid intake, medical conditions, collection timing, or intentional conduct. Substitution refers to a submitted specimen that is not consistent with the expected donor urine. Adulteration refers to adding or introducing a substance that can disrupt detection or validity testing.

Those categories have different analytical indicators. A laboratory should report the measurement actually made and the rule used to classify it. A label without the underlying creatinine, specific gravity, pH, oxidant, nitrite, temperature, and timing data is difficult to evaluate independently.

What the contamination study shows

Rienluek evaluated prepared urine specimens containing methamphetamine and selected contaminants using a CEDIA method and an immunochromatographic method. Under the study’s specific conditions, several contaminants produced false-negative or indeterminate screening outcomes.

The paper demonstrates analytical vulnerability, not a universal recipe and not proof of tampering in a particular case. The findings depend on the tested products, target concentrations, contaminant conditions, and laboratory procedure. They should not be transferred automatically to a different assay, cutoff, or specimen.

The practical lesson is narrower and more useful: when an unexpected screen is accompanied by abnormal specimen-validity findings, the reviewer should obtain the raw validity measurements, the exact assay instructions, quality-control records, and confirmatory data before drawing a conclusion.

A negative screen can have several explanations

An analyte may be absent, below the cutoff, outside the panel, poorly recognized by the assay, or reduced by dilution. An interferent may also change a specific test response. These explanations are analytically different even if the final screen is reported as negative.

Confirmation by chromatography and mass spectrometry can improve chemical specificity, but confirmation still depends on what analytes were included, the reporting cutoffs, specimen preparation, and whether the laboratory recognized a validity problem. A narrow confirmation panel cannot identify every possible drug, metabolite, or interferent.

Do not infer intent from one abnormal number

Specimen-validity findings can support additional investigation. They do not automatically establish why the result occurred. Medical history, hydration, renal function, collection observation, specimen temperature, collection timing, handling, storage, chain of custody, and the laboratory’s classification criteria may all matter.

A case-specific opinion should distinguish:

• what was directly measured;
• what classification rule was applied;
• what analytical explanations remain possible;
• whether the drug screen and validity tests were repeated;
• whether an independent specific method was used; and
• which conclusions concern chemistry, rather than motive or intent.

Records needed for a reliable review

Request the complete laboratory packet, including:

• collection time, receipt time, and specimen temperature;
• creatinine, specific gravity, pH, oxidant, and nitrite results;
• the laboratory’s validity thresholds and classification rules;
• the screening manufacturer, assay, lot, expiration date, and cutoff;
• raw instrument output and operator observations;
• calibration and positive and negative quality-control records;
• confirmation method, target analytes, internal standards, and cutoffs;
• dilution, repeat-testing, and recollection procedures;
• storage conditions and chain-of-custody documentation; and
• relevant medical, medication, supplement, and fluid-intake history.

The most reliable conclusion is often not that one abnormal result proves manipulation. It is that the result must be interpreted within the complete specimen-validity, analytical, and chain-of-custody record.

References

• Rienluek S. Effects of contaminants on urine methamphetamine screening test. Journal of the Medical Technologist Association of Thailand. 2016;44(1).
• Reisfield GM, Goldberger BA, Bertholf RL. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952. https://doi.org/10.4155/bio.09.81
• Markway EC, Baker SN. A review of the methods, interpretation, and limitations of the urine drug screen. Orthopedics. 2011;34(11):877-881. https://doi.org/10.3928/01477447-20110922-22
• Wilkening GL, Hale GM, Ross C. Urine drug screens: considerations for the psychiatric pharmacist. Mental Health Clinician. 2016;6(1):42-47. https://doi.org/10.9740/mhc.2016.01.042

Educational information only. It is not a case-specific toxicology opinion or legal advice.